Company: PRME
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038619
Chunk: 34

Company: Prime Medicine, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
 EndedJune 30,Six Months EndedJune 30,(in thousands, except share and per share amounts)2025202420252024Revenue:Collaboration revenue — related party$1,115 $— $2,569 $— Collaboration revenue— — — 591 Total revenue1,115 — 2,569 591 Operating expenses:Research and development41,375 43,071 81,937 80,845 General and administrative13,117 12,601 26,401 23,759 Total operating expenses54,492 55,672 108,338 104,604 Loss from operations(53,377)(55,672)(105,769)(104,013)Other income:Interest income743 611 1,925 1,287 Accretion (amortization) of investments530 1,486 869 2,316 Change in fair value of short-term investment — related party(505)(1,925)(1,561)(759)Other income, net18 39 55 81 Total other income, net786 211 1,288 2,925 Net loss before income taxes(52,591)(55,461)(104,481)(101,088)Provision for income taxes— 134 — — Net loss attributable to common stockholders$(52,591)$(55,327)$(104,481)$(101,088)Net loss per share attributable to common stockholders, basic and diluted$(0.41)$(0.46)$(0.81)$(0.90)Weighted-average common shares outstanding, basic and diluted129,185,918 119,188,866 128,439,349 111,827,522 Comprehensive loss:Net loss$(52,591)$(55,327)$(104,481)$(101,088)Change in unrealized loss on investments, net of tax5 24 (11)(56)Comprehensive loss$(52,586)$(55,303)$(104,492)$(101,144)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

6

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

Common StockAdditionalPaid-inCapitalAccumulated OtherComprehensiveLoss